title: Elevated circulating lipocalin-2 levels independently predict incident cardiovascular events in men in a population-based cohort.
abstract: OBJECTIVE
  Adipose tissue inflammation and perturbation of adipokine secretion may contribute to the pathogenesis of cardiovascular diseases (CVD). Lipocalin-2 (LCN2), mainly released from adipocytes, has been shown to be positively associated with CVD in cross-sectional studies. We aimed to evaluate the association of LCN2 with CVD involving a population-based cohort recruited from the Shanghai Diabetes Study.
  
  
  RESULTS
  Serum LCN2 levels were measured using ELISA. Independent predictors of CVD development were identified using Cox proportion hazards regression. The predictive performances of the various models were assessed by Kaplan-Meier analysis. At baseline, circulating LCN2 was significantly associated with a cluster of traditional cardiovascular risk factors. Baseline LCN2 levels in male subjects who developed CVD events during follow-up were significantly higher than those who did not develop CVD events (P=0.012). However, such difference was not significant in female subjects. LCN2 was a predictor of CVD in men, which remained statistically significant after adjustment for traditional cardiovascular risk factors (hazard ratio, 1.038 [95% confidence interval, 1.017-1.060]). LCN2 remained significantly associated with incident CVD even after adjustment for renal function, adiponectin, and high-sensitivity C-reactive protein levels. Kaplan-Meier analysis suggested combination of LCN2 and high-sensitivity C-reactive protein might improve the prediction of CVD events in male subjects.
  
  
  CONCLUSIONS
  Elevated circulating LCN2 level is an independent predictor of CVD events in men in a population-based cohort and adds to the prognostic value of high-sensitivity C-reactive protein, which is currently the most extensively studied biomarker of CVD. Measurement of serum LCN2 might be useful for early detection and intervention of CVD.
authors.affiliation: From the Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Key Clinical Center for Metabolic Disease, Shanghai, China (G.W., H.L., Q.F., S.J., L.Z., J.Z., X.H., J.L., Y.B., W.J.); and Department of Medicine, State Key Laboratory of Pharmaceutical Biotechnology (A.X.) and Department of Pharmacology and Pharmacy (A.X.), University of Hong Kong, Hong Kong, China.
authors.forename: Guangyu
authors.initials: G
authors.lastname: Wu
authors.affiliation: From the Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Key Clinical Center for Metabolic Disease, Shanghai, China (G.W., H.L., Q.F., S.J., L.Z., J.Z., X.H., J.L., Y.B., W.J.); and Department of Medicine, State Key Laboratory of Pharmaceutical Biotechnology (A.X.) and Department of Pharmacology and Pharmacy (A.X.), University of Hong Kong, Hong Kong, China.
authors.forename: Huating
authors.initials: H
authors.lastname: Li
authors.affiliation: From the Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Key Clinical Center for Metabolic Disease, Shanghai, China (G.W., H.L., Q.F., S.J., L.Z., J.Z., X.H., J.L., Y.B., W.J.); and Department of Medicine, State Key Laboratory of Pharmaceutical Biotechnology (A.X.) and Department of Pharmacology and Pharmacy (A.X.), University of Hong Kong, Hong Kong, China.
authors.forename: Qichen
authors.initials: Q
authors.lastname: Fang
authors.affiliation: From the Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Key Clinical Center for Metabolic Disease, Shanghai, China (G.W., H.L., Q.F., S.J., L.Z., J.Z., X.H., J.L., Y.B., W.J.); and Department of Medicine, State Key Laboratory of Pharmaceutical Biotechnology (A.X.) and Department of Pharmacology and Pharmacy (A.X.), University of Hong Kong, Hong Kong, China.
authors.forename: Shan
authors.initials: S
authors.lastname: Jiang
authors.affiliation: From the Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Key Clinical Center for Metabolic Disease, Shanghai, China (G.W., H.L., Q.F., S.J., L.Z., J.Z., X.H., J.L., Y.B., W.J.); and Department of Medicine, State Key Laboratory of Pharmaceutical Biotechnology (A.X.) and Department of Pharmacology and Pharmacy (A.X.), University of Hong Kong, Hong Kong, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Zhang
authors.affiliation: From the Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Key Clinical Center for Metabolic Disease, Shanghai, China (G.W., H.L., Q.F., S.J., L.Z., J.Z., X.H., J.L., Y.B., W.J.); and Department of Medicine, State Key Laboratory of Pharmaceutical Biotechnology (A.X.) and Department of Pharmacology and Pharmacy (A.X.), University of Hong Kong, Hong Kong, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Zhang
authors.affiliation: From the Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Key Clinical Center for Metabolic Disease, Shanghai, China (G.W., H.L., Q.F., S.J., L.Z., J.Z., X.H., J.L., Y.B., W.J.); and Department of Medicine, State Key Laboratory of Pharmaceutical Biotechnology (A.X.) and Department of Pharmacology and Pharmacy (A.X.), University of Hong Kong, Hong Kong, China.
authors.forename: Xuhong
authors.initials: X
authors.lastname: Hou
authors.affiliation: From the Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Key Clinical Center for Metabolic Disease, Shanghai, China (G.W., H.L., Q.F., S.J., L.Z., J.Z., X.H., J.L., Y.B., W.J.); and Department of Medicine, State Key Laboratory of Pharmaceutical Biotechnology (A.X.) and Department of Pharmacology and Pharmacy (A.X.), University of Hong Kong, Hong Kong, China.
authors.forename: Junxi
authors.initials: J
authors.lastname: Lu
authors.affiliation: From the Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Key Clinical Center for Metabolic Disease, Shanghai, China (G.W., H.L., Q.F., S.J., L.Z., J.Z., X.H., J.L., Y.B., W.J.); and Department of Medicine, State Key Laboratory of Pharmaceutical Biotechnology (A.X.) and Department of Pharmacology and Pharmacy (A.X.), University of Hong Kong, Hong Kong, China.
authors.forename: Yuqian
authors.initials: Y
authors.lastname: Bao
authors.affiliation: From the Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Key Clinical Center for Metabolic Disease, Shanghai, China (G.W., H.L., Q.F., S.J., L.Z., J.Z., X.H., J.L., Y.B., W.J.); and Department of Medicine, State Key Laboratory of Pharmaceutical Biotechnology (A.X.) and Department of Pharmacology and Pharmacy (A.X.), University of Hong Kong, Hong Kong, China.
authors.forename: Aimin
authors.initials: A
authors.lastname: Xu
authors.affiliation: From the Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Key Clinical Center for Metabolic Disease, Shanghai, China (G.W., H.L., Q.F., S.J., L.Z., J.Z., X.H., J.L., Y.B., W.J.); and Department of Medicine, State Key Laboratory of Pharmaceutical Biotechnology (A.X.) and Department of Pharmacology and Pharmacy (A.X.), University of Hong Kong, Hong Kong, China. wpjia@sjtu.edu.cn.
authors.forename: Weiping
authors.initials: W
authors.lastname: Jia
mesh_terms: D000209:Acute-Phase Proteins; D000368:Aged; D044466:Asian People; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000097:blood* / Q000175:diagnosis / Q000453:epidemiology*; D002681:China; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D000071068:Lipocalin-2; D054834:Lipocalins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000097:blood*; D012307:Risk Factors
chemical_list: D000209:Acute-Phase Proteins; D015415:Biomarkers; C489506:LCN2 protein, human; D000071068:Lipocalin-2; D054834:Lipocalins; D011518:Proto-Oncogene Proteins; D002097:C-Reactive Protein
keywords: LCN2 protein, human; adipokines; biomarkers; cardiovascular diseases